The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.

MLA

Behr, Juergen, et al. “The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.” American Journal of Respiratory & Critical Care Medicine, vol. 210, no. 4, Aug. 2024, pp. 392–400. EBSCOhost, https://doi.org/10.1164/rccm.202401-0048PP.

APA

Behr, J., Salisbury, M. L., Walsh, S. L. F., Podolanczuk, A. J., Hariri, L. P., Hunninghake, G. M., Kolb, M., Ryerson, C. J., Cottin, V., Beasley, M. B., Corte, T., Glanville, A. R., Adegunsoye, A., Hogaboam, C., Wuyts, W. A., Noth, I., Oldham, J. M., Richeldi, L., Raghu, G., & Wells, A. U. (2024). The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions. American Journal of Respiratory & Critical Care Medicine, 210(4), 392–400. https://doi.org/10.1164/rccm.202401-0048PP

Chicago

Behr, Juergen, Margaret L. Salisbury, Simon L. F. Walsh, Anna J. Podolanczuk, Lida P. Hariri, Gary M. Hunninghake, Martin Kolb, et al. 2024. “The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.” American Journal of Respiratory & Critical Care Medicine 210 (4): 392–400. doi:10.1164/rccm.202401-0048PP.